Organovo Holdings, Inc. (0R02.L)
USD 0.38
(-3.43%)
USD 0.38
(-3.43%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 14.91 Million USD | -17.6% |
| 2022 | 18.1 Million USD | 39.46% |
| 2021 | 12.97 Million USD | -22.86% |
| 2020 | 16.82 Million USD | -27.92% |
| 2019 | 23.34 Million USD | -21.89% |
| 2018 | 29.88 Million USD | -23.07% |
| 2017 | 38.84 Million USD | -7.18% |
| 2016 | 41.84 Million USD | 4.29% |
| 2015 | 40.12 Million USD | 29.99% |
| 2014 | 30.86 Million USD | 46.79% |
| 2013 | 21.02 Million USD | 99.96% |
| 2012 | 10.51 Million USD | 0.0% |
| 2010 | 120.09 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.35 Million USD | 9.75% |
| 2023 Q3 | 3.68 Million USD | -10.45% |
| 2023 Q1 | 4.27 Million USD | -46.23% |
| 2023 Q2 | 4.11 Million USD | -3.63% |
| 2023 FY | 14.91 Million USD | -17.6% |
| 2023 Q4 | 3.05 Million USD | -17.1% |
| 2022 FY | 18.1 Million USD | 39.46% |
| 2022 Q4 | 7.94 Million USD | 127.54% |
| 2022 Q3 | 3.49 Million USD | 1.72% |
| 2022 Q2 | 3.43 Million USD | 5.93% |
| 2022 Q1 | 3.23 Million USD | -5.1% |
| 2021 Q1 | 2.55 Million USD | -1.5% |
| 2021 Q2 | 3.5 Million USD | 37.05% |
| 2021 FY | 12.97 Million USD | -22.86% |
| 2021 Q4 | 3.41 Million USD | -2.49% |
| 2021 Q3 | 3.5 Million USD | -0.2% |
| 2020 Q1 | 2.78 Million USD | -3.7% |
| 2020 Q4 | 2.59 Million USD | 4.25% |
| 2020 Q2 | 8.95 Million USD | 221.25% |
| 2020 FY | 16.82 Million USD | -27.92% |
| 2020 Q3 | 2.49 Million USD | -72.16% |
| 2019 Q2 | 7.79 Million USD | 9.18% |
| 2019 FY | 23.34 Million USD | -21.89% |
| 2019 Q4 | 2.89 Million USD | -47.58% |
| 2019 Q3 | 5.51 Million USD | -29.18% |
| 2019 Q1 | 7.13 Million USD | -7.79% |
| 2018 Q1 | 8.14 Million USD | -3.08% |
| 2018 FY | 29.88 Million USD | -23.07% |
| 2018 Q4 | 7.74 Million USD | 7.98% |
| 2018 Q3 | 7.16 Million USD | 5.01% |
| 2018 Q2 | 6.82 Million USD | -16.19% |
| 2017 Q2 | 10.68 Million USD | -1.92% |
| 2017 Q1 | 10.88 Million USD | -3.78% |
| 2017 Q4 | 8.4 Million USD | -5.24% |
| 2017 FY | 38.84 Million USD | -7.18% |
| 2017 Q3 | 8.87 Million USD | -16.95% |
| 2016 Q2 | 10.46 Million USD | 10.13% |
| 2016 Q4 | 11.31 Million USD | 7.07% |
| 2016 FY | 41.84 Million USD | 4.29% |
| 2016 Q1 | 9.5 Million USD | 5.79% |
| 2016 Q3 | 10.57 Million USD | 1.03% |
| 2015 FY | 40.12 Million USD | 29.99% |
| 2015 Q4 | 8.98 Million USD | -16.84% |
| 2015 Q3 | 10.79 Million USD | -6.79% |
| 2015 Q2 | 11.58 Million USD | 32.19% |
| 2015 Q1 | 8.76 Million USD | 6.4% |
| 2014 Q1 | 6.5 Million USD | -4.29% |
| 2014 FY | 30.86 Million USD | 46.79% |
| 2014 Q4 | 8.23 Million USD | 15.75% |
| 2014 Q3 | 7.11 Million USD | -20.99% |
| 2014 Q2 | 9 Million USD | 38.36% |
| 2013 FY | 21.02 Million USD | 99.96% |
| 2013 Q2 | 5.62 Million USD | 46.48% |
| 2013 Q1 | 3.84 Million USD | -9.43% |
| 2013 Q4 | 6.8 Million USD | 42.85% |
| 2013 Q3 | 4.76 Million USD | -15.36% |
| 2012 Q1 | 1.7 Million USD | 17.91% |
| 2012 Q2 | 4.08 Million USD | 139.19% |
| 2012 Q3 | 3.27 Million USD | -19.96% |
| 2012 Q4 | 4.24 Million USD | 29.61% |
| 2012 FY | 10.51 Million USD | 0.0% |
| 2011 Q2 | 25.12 Thousand USD | -39.77% |
| 2011 Q1 | 41.71 Thousand USD | 82.66% |
| 2011 Q3 | 43.5 Thousand USD | 73.18% |
| 2011 Q4 | 1.44 Million USD | 3230.87% |
| 2010 Q2 | 25.72 Thousand USD | 0.0% |
| 2010 Q3 | 29.82 Thousand USD | 15.96% |
| 2010 Q4 | 22.83 Thousand USD | -23.44% |
| 2010 FY | 120.09 Thousand USD | 0.0% |
| 2009 Q4 | 17.62 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 91.145% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 96.654% |
| Codexis, Inc. | 66.51 Million USD | 77.577% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 94.146% |